Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Mars has not offered remedies to EU for Kellanova deal, EU website shows
    Finance

    Mars has not offered remedies to EU for Kellanova deal, EU website shows

    Published by Global Banking & Finance Review®

    Posted on June 19, 2025

    2 min read

    Last updated: January 23, 2026

    Mars has not offered remedies to EU for Kellanova deal, EU website shows - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:portfoliosfinancial sectorInvestment management

    Quick Summary

    Mars has not proposed remedies for its $36B Kellanova acquisition, leading to potential EU investigation over antitrust concerns.

    Mars Fails to Propose Remedies for Kellanova Acquisition to EU

    By Foo Yun Chee

    BRUSSELS (Reuters) -Candy company Mars has not offered remedies to EU antitrust regulators reviewing its proposed $36-billion takeover of Pringles maker Kellanova, an update on the European Commission website showed on Thursday.

    The deadline for Mars to offer remedies was June 18.

    Mars and Kellanova did not immediately respond to emailed requests for comment.

    Reuters reported on Wednesday that Mars was unlikely to offer remedies for now to address the EU competition enforcer's concerns about its high market share in certain products in some European Union countries and its portfolio of strong brands.

    People close to the matter said the EU antitrust watchdog will launch a full-scale investigation into the deal at the end of its preliminary review which finishes on June 25.

    An EU investigation could force Mars to divest assets to allay competition concerns.

    But the bar is high for regulators to prove anti-competitive harm caused by so-called portfolio effects, which refer to a combined portfolio of products boosting a company's dominant position or creating market power.

    It is also difficult to find remedies to address portfolio effects.

    The deal, announced last August, is one of the biggest in a sector dealing with the impact of inflation-weary belt-tightening consumers and a shift to private label brands.

    The transaction brings brands from M&Ms and Snickers to Pringles and Pop-Tarts under one roof.

    (Reporting by Foo Yun Chee. Editing by Jane Merriman)

    Key Takeaways

    • •Mars has not offered remedies for its Kellanova acquisition to the EU.
    • •The EU may launch a full-scale investigation into the deal.
    • •Mars' acquisition could face divestiture to address competition concerns.
    • •The deal is significant amidst consumer shifts to private labels.
    • •Portfolio effects pose challenges in proving anti-competitive harm.

    Frequently Asked Questions about Mars has not offered remedies to EU for Kellanova deal, EU website shows

    1What is the status of Mars' proposed acquisition of Kellanova?

    Mars has not offered remedies to EU antitrust regulators for its $36-billion takeover of Kellanova, which is currently under review.

    2What is the deadline for Mars to propose remedies?

    The deadline for Mars to offer remedies to the EU was June 18.

    3What could happen if the EU investigates the deal?

    A full-scale investigation by the EU could lead Mars to divest assets to address competition concerns.

    4What challenges do regulators face in proving anti-competitive harm?

    Regulators face a high bar to prove anti-competitive harm due to portfolio effects, which complicate finding effective remedies.

    5What brands would be combined under the proposed deal?

    The deal would combine brands such as M&Ms, Snickers, Pringles, and Pop-Tarts under one roof.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostECB's next move on rates most likely a cut, Villeroy says
    Next Finance PostExclusive-Syria made first direct international bank transfer via SWIFT since war, central bank governor says